Preventability of cancer: The relative contributions of biologic and social and physical environmental determinants of cancer mortality

Annual Review of Public Health

Volumn 33, Issue , 2012, Pages 137-156

  Colditz, Graham A ^a   Wei, Esther K ^b  

^a MO   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Activity; Built environment; Chemoprevention; Obesity; Tobacco

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CHEMOPROPHYLAXIS; ENVIRONMENTAL FACTOR; HUMAN; PRIORITY JOURNAL; REVIEW;

ENVIRONMENTAL EXPOSURE; HEALTH STATUS DISPARITIES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84861411076     PISSN: 01637525     EISSN: 15452093     Source Type: Book Series    
DOI: 10.1146/annurev-publhealth-031811-124627     Document Type: Review

References (113)

1. Armitage P, Doll R. 1954. The age distribution of cancer and a multistage theory of carcinogenesis. Br. J. Cancer 8:1-12
2. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, et al. 2010. Once-only flexible sigmoid-oscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375:1624-33
3. Atwood K, Colditz GA, Kawachi I. 1997. From public health science to prevention policy: placing science in its social and political contexts. Am. J. Public Health 87:1603-6
4. Baer HJ, Tworoger SS, Hankinson SE, Willett WC. 2010. Body fatness at young ages and risk of breast cancer throughout life. Am. J. Epidemiol. 171:1183-94
5. Bailar JC, Gornick HL. 1997. Cancer undefeated. N. Engl. J. Med. 336:1569-74
6. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, et al. 1999. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N. Engl. J. Med. 340:101-7
7. Beral V, Reeves G, Bull D, Green J. 2011. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl. Cancer Inst. 103:296-305
8. Boffetta P. 2004. Epidemiology of environmental and occupational cancer. Oncogene 23:6392-403
9. Boffetta P, McLaughlin JK, La Vecchia C. 2008. Reply: 'environment' in cancer causation and etiological fraction: limitations and ambiguities (by Boffetta, P. et al. 2007. Carcinogenesis 28:913-15). Carcinogenesis 29:1850
10. Boffetta P, McLaughlin JK, La Vecchia C, Autier P, Boyle P. 2007. 'Environment' in cancer causation and etiological fraction: limitations and ambiguities. Carcinogenesis 28:913-15
11. Brown CC, Chu KC. 1987. Use of multistage models to infer stage affected by carcinogenic exposure: example of lung cancer and cigarette smoking. J. Chronic Dis. 40(Suppl. 2):S171-79
12. Byers T, Mouchawar J, Marks J, Cady B, Lins N, et al. 1999. The American Cancer Society challenge goals. How far can cancer rates decline in the U.S. by the year 2015? Cancer 86:715-27
13. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348:1625-38
14. Cent. Dis. Control Prev. (CDC). 2010. State-specific prevalence of cigarette smoking and smokeless tobacco use among adults\United States, 2009. MMWR 59:1400-6
15. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. 2005. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914-23
16. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, et al. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336:1855-59
17. Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, et al. 2005. Preventionofhepatocellularcarcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin. Cancer Res. 11:7953-57
18. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, et al. 2009. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst. 101:1348-55
19. Chen WY, Rosner B, Colditz GA. 2007. Moving forwardwith breast cancer prevention.Cancer 109:2387-91
20. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, et al. 2009. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360:573-87
21. Cho E, Rosner BA, Feskanich D, Colditz GA. 2005. Risk factors and individual probabilities of melanoma for whites. J. Clin. Oncol. 23:2669-75
22. Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, et al. 2004. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J. Natl. Cancer Inst. 96:1015-22
23. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. 2006. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J. Clin. Oncol. 24:e49-50
24. Colditz GA. 2007. Cohort studies of etiology and survival after cancer: the unique needs for uninterrupted funding. Cancer Causes Control 18:235-41
25. Colditz GA. 2007. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res. 9:108
26. Colditz GA. 2010. Ensuring long-term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control. Cancer Causes Control 21:649-56
27. Colditz GA, De Jong D, Hunter DJ, Trichopoulos D, Willett WC, eds. 1996. Harvard Report on Cancer Prevention. Volume 1: Causes of Human Cancer. Cancer Causes Control 7(Suppl.) 1-59
28. Colditz GA, Rosner B. 2000. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am. J. Epidemiol. 152:950-64
29. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. 2004. Risk factors for breast cancer according to estrogen and progesterone receptor status. J. Natl. Cancer Inst. 96:218-28
30. Colditz GA, Rosner BA, Speizer FE. 1996. Risk factors for breast cancer according to family history of breast cancer. J. Natl. Cancer Inst. 88:365-71
31. Colditz GA, Sellers TA, Trapido E. 2006. Epidemiology\identifying the causes and preventability of cancer? Nat. Rev. Cancer 6:75-83
32. Colditz GA, Taylor PR. 2010. Prevention trials: their place in how we understand the value of prevention strategies. Annu. Rev. Public Health 31:105-20
33. Collab. Group Epidemiol. Stud. Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. 2008. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 371:303-14
34. Collab. Group Horm. Factors Breast Cancer. 1997. Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies involving 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350:1047-59
35. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, et al. 2010. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 10:675
36. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. 2005. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366:1784-93
37. Day NE. 1990. The Armitage-Doll multistage model of carcinogenesis. Stat. Med. 9:677-79
38. Doll R, Peto R. 1978. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J. Epidemiol. Community Health 32:303-13
39. Doll R, Peto R. 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66:1191-308
40. Durand CP, Andalib M, Dunton GF, Wolch J, Pentz MA. 2011. A systematic review of built environment factors related to physical activity and obesity risk: implications for smart growth urban planning. Obes. Rev. Off. J. Int. Assoc. Study Obes. 12:e173-82
41. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, et al. 2010. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-73
42. Epstein S, Swartz J. 1981. Fallacies of lifestyle cancer theories. Nature 289:127-30
43. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371-88
44. Fisher JC, Hollomon JH. 1951. A hypothesis for the origin of cancer foci. Cancer 4:916-18
45. Flossmann E, Rothwell PM. 2007. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-13
46. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. 2000. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284:1954-61
47. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, et al. 2005. Cancer risk prediction models: a workshop on development, evaluation, and application. J. Natl. Cancer Inst. 97:715-23
48. Gehlert S, Sohmer D, Sacks T, Mininger C, McClintock M, Olopade O. 2008. Targeting health disparities: a model linking upstream determinants to downstream interventions. Health Aff. 27:339-49
49. Glasziou PP, Irwig LM. 1995. An evidence based approach to individualising treatment. BMJ 311:1356-59
50. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, et al. 2008. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening\a report from the American Society of Clinical Oncology. J. Clin. Oncol. 26:313-25
51. Haber DA, Gray NS, Baselga J. 2011. The evolving war on cancer. Cell 145:19-24
52. Hazelton WD, Clements MS, Moolgavkar SH. 2005. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol. Biomark. Prev. 14:1171-81
53. Int. Agency Res. Cancer (IARC). 2002. Weight Control and Physical Activity. Lyon: IARC. 315 pp
54. Int. Agency Res. Cancer (IARC). 2007. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr. Eval. Carcinog. Risks Hum. 91:1-528
55. Int. Agency Res. Cancer (IARC). 2008. World Cancer Report 2008. Lyon: IARC
56. Kaldor J, Day N. 1996. Mathematical models in cancer epidemiology. In Cancer Epidemiology, ed. D Schottenfeld, J Fraumeni, pp. 127-37. New York: Oxford Univ. Press
57. Kawachi I, Colditz GA, Hankinson S. 1994. Long-term benefits and risks of alternative methods of fertility control in the United States. Contraception 50:1-16
58. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. 2008. Smoking and smoking cessation in relation to mortality in women. JAMA 299:2037-47
59. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. 2007. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J. Natl. Cancer Inst. 99:1335-39
60. Kim D, Masyn KE, Kawachi I, Laden F, Colditz GA. 2010. Neighborhood socioeconomic status and behavioral pathways to risks of colon and rectal cancer in women. Cancer 116:4187-96
61. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68:820-23
62. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-51
63. Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, et al. 2011. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am. J. Clin. Nutr. 93:817-25
64. Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo W, et al. 2002. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br. J. Cancer 87:982-88
65. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, et al. 2008. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J. Natl. Cancer Inst. 100:1352-60
66. Little M, Hawkins M, Charles M, Hildreth N. 1992. Fitting the Armitage-Doll model to radiation-exposed cohorts and implications for population cancer risks. Radiat. Res. 132:207-21
67. Luebeck EG. 2010. Cancer: genomic evolution of metastasis. Nature 467:1053-55
68. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, et al. 2004. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. 96:1751-61
69. Meza R, Jeon J, Moolgavkar SH, Luebeck EG. 2008. Age-specific incidence of cancer: phases, transitions, and biological implications. Proc. Natl. Acad. Sci. USA 105:16284-89
70. Miettinen OS. 1974. Proportion of disease caused and prevented by a given exposure, trait, or intervention. Am. J. Epidemiol. 99:325-33
71. Mills PK, Beeson WL, Phillips RL, Fraser GE. 1994. Cancer incidence among California Seventh-Day Adventists, 1976-1982. Am. J. Clin. Nutr. 59:S1136-42
72. Monson RR, Christiani DC. 1997. Summary of the evidence: occupation and environment and cancer. Cancer Causes Control 8:529-31
73. Montague M, Borland R, Sinclair C. 2001. Slip! Slop! Slap! and Sun Smart, 1980-2000: skin cancer control and 20 years of population-based campaigning. Health Educ. Behav. 28:290-305
74. Moolgavkar SH. 1990. Cancer models. Epidemiology 1:419-20
75. Moolgavkar SH, Day NE, Stevens RG. 1980. Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J. Natl. Cancer Inst. 65:559-69
76. Moore LV, Diez Roux AV. 2006. Associations of neighborhood characteristics with the location and type of food stores. Am. J. Public Health 96:325-31
77. Natl. Program Cancer Regist. 2011. United States Cancer Statistics. http://apps.nccd.cdc.gov/uscs/statevsnational.aspx
78. Nimptsch K, Giovannucci EL, Willett WC, Fuchs C, Wei EK, Wu K. 2011. Body fatness during childhood and adolescence, adult height and risk of colorectal adenoma in women. Cancer Prev. Res. 4:1710-18
79. Nordling CO. 1953. A new theory on cancer-inducing mechanism. Br. J. Cancer 7:68-72
80. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-44
81. Peto R, Chen ZM, Boreham J. 1999. Tobacco\the growing epidemic. Nat. Med. 5:15-17
82. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. 2000. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321:323-29
83. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. 1996. Mortality from smoking worldwide. Br. Med. Bull. 52:12-21
84. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 1983. "Hormonal" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature 303:767-70
85. Prev. Work. Group. 1986. Cancer control objectives for the nation: 1985-2000. NCI Monogr. 2:3-11
86. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, et al. 2007. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356:1670-74
87. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. 2008. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-78
88. Rosner B, Colditz GA. 1996. Nurses' health study: log-incidence mathematical model of breast cancer incidence. J. Natl. Cancer Inst. 88:359-64
89. Rosner B, Colditz GA, Willett WC. 1994. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am. J. Epidemiol. 139:819-35
90. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-33
91. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. 2011. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41
92. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, et al. 2010. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-50
93. Salois MJ. 2011. Obesity and diabetes, the built environment, and the 'local' food economy in the United States, 2007. Econ. Hum. Biol. In press
94. Tarlov AR, St. Peter RF. 2000. Introduction. In The Society and Population Health Reader: Vol. II. A State and Community Perspective, ed. AR Tarlov, RF St. Peter, pp. x-xi. New York: New Press
95. U.S. Dep. Health Hum. Serv. 2004. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta: Cent. Dis. Control Prev.
96. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG. 2010. Tobacco and cancer: an American Association for Cancer Research policy statement. Cancer Res. 70:3419-30
97. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319:525-32
98. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, et al. 2008. Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities. Am. J. Public Health 98:1608-15
99. Waters EA, Weinstein ND, Colditz GA, Emmons K. 2009. Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol. 28:201-9
100. Wei E, Giovannucci E, Liu J, Fuchs C, Willett W, et al. 2005. A prospective study of birthweight, height and body mass index at age 18 and the risk of colon cancer in women. Cancer Epidemiol. Biomark. Prev. 14:S2758-59
101. Wei EK, Colditz GA, Giovannucci EL, Fuchs CS, Rosner BA. 2009. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study. Am. J. Epidemiol. 170:863-72
102. Wei EK, Wolin KY, Colditz GA. 2010. Time course of risk factors in cancer etiology and progression. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28:4052-57
103. Weil D. 2003. OSHA: Beyond the politics. Frontline (online). http://www.pbs.org/wgbh/pages/frontline/shows/workplace/osha/weil.html
104. Willett WC, Colditz GA, Mueller NE. 1996. Strategies for minimizing cancer risk. Sci. Am. 275:88-95
105. Wolin KY, Carson K, Colditz GA. 2010. Obesity and cancer. Oncologist 15:556-65
106. Wolin KY, Colditz GA. 2011. Implementing chronic disease prevention amongst cancer survivors. J. Intern. Med. 269:85-87
107. World Cancer Res. Fund. 2007. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: Am. Inst. Cancer Res.
108. World Health Organ. 2006. Elimination of Asbestos-related Disease. Geneva: WHO
109. World Health Organ. 2007. Cancer Control: Knowledge into Action (Prevention Module). Geneva: WHO
110. Xu Z, Brown LM, Pan GW, Liu TF, Gao GS, et al. 1996. Cancer risks among iron and steel workers in Anshan, China, Part II: case-control studies of lung and stomach cancer. Am. J. Ind. Med. 30:7-15
111. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-17
112. Zelen M. 1988. Are primary cancer prevention trials feasible? J. Natl. Cancer Inst. 80:1442-44
113. Ziegler RG, Anderson WF, Gail MH. 2008. Increasing breast cancer incidence in China: the numbers add up. J. Natl. Cancer Inst. 100:1339-41